MedTrace Logo

MIcronized Flavonoid Fraction After MechanO-Chemical Ablation

NCT04434274 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-11-16

No results posted yet for this study

Summary

This study will be evaluate the clinical efficacy of micronized purified flavonoid fraction (MPFF) phlebotropic therapy for postoperative pain, venospecific symptoms, and quality of life in patients with incompetent great or small saphenous veins (GSV/SSV) following an endovenous mechanochemical ablation procedure (MOCA).

Conditions

  • Varicose Veins
  • Surgery

Interventions

DRUG

Micronized Purified Flavonoid Fraction

Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.

Sponsors & Collaborators

  • Belarusian State Medical University

    lead OTHER

Principal Investigators

  • Vladimir Khryshchanovich, MD, Prof · Educational Institution "Belarusian State Medical University"

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-06-18
Completion
2022-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04434274 on ClinicalTrials.gov